July 24 2016:
A meta-analysis published in the International Journal of Laboratory Haematology suggests that monitoring warfarin with Fiix-PT reduces risk of vascular events in NVAF patients at least as much as DOACs.
Compared to traditionally INR monitored warfarin, Fiix-warfarin (warfarin monitored with Fiix-PT) is an improved anticoagulant.

June 7 2016:
A publication in the May 2016 issue of the Journal of Thrombosis and Haemastasis demonstrates that the dilute Fiix prothrombin time may be suitable as a stat test to assess all oral anticoagulants as well as unfractionated and fractionated heparin.

Pall T. Onundarson, M.D. ( and Brynja R. Gudmundsdottir, M.S. (
+534-543-5010 (Pall) and +534-861-2662 (Brynja) Email:
Kleifarvegur 12, 104 Reykjavik, Iceland